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ABSTRACT
Objective: To determine the incremental value of
ambulatory blood pressure (BP) in predicting
cardiovascular risk when the Framingham Risk Score
(FRS) is known.
Methods: We included 780 men without
cardiovascular disease from the Uppsala Longitudinal
Study of Adult Men, all aged approximately 70 years at
baseline. We first screened ambulatory systolic BP
(ASBP) parameters for their incremental value by
adding them to a model with 10-year FRS. For the best
ASBP parameter we estimated HRs and changes in
discrimination, calibration and reclassification. We also
estimated the difference in the number of men started
on treatment and in the number of men protected
against a cardiovascular event.
Results: Mean daytime ASBP had the highest
incremental value; adding other parameters did not yield
further improvements. While ASBP was an independent
risk factor for cardiovascular disease, addition to FRS
led to only small increases to the overall model fit,
discrimination (a 1% increase in the area under the
receiver operating characteristic (ROC) curve),
calibration and reclassification. We estimated that for
every 10 000 men screened with ASBP, 141 fewer
would start a new BP-lowering treatment (95% CI 62 to
220 less treated), but this would result in
7 fewer cardiovascular events prevented over the
subsequent 10 years (95% CI 21 fewer events
prevented to 7 more events prevented).
Conclusions: In addition to a standard cardiovascular
risk assessment it is not clear that ambulatory BP
measurement provides further incremental value. The
clinical role of ambulatory BP requires ongoing careful
consideration.
INTRODUCTION
There is increasing interest in measuring
patients’ ambulatory blood pressure (BP), both
to conﬁrm a diagnosis of hypertension and to
monitor response to treatment. For example,
the UK’s National Institute for Health and
Care Excellence (NICE) 2011 guidelines on
hypertension recommend the use of ambula-
tory BP measurement to conﬁrm the diagnosis
of hypertension in all patients using the mean
of measurements taken during waking hours.1
Ambulatory BP monitoring (ABPM) uses mea-
surements made by an automated device over a
24 h period and has a number of potential
advantages. There is less likely to be ‘white coat
hypertension’ where BP is raised because the
patient is anxious about the measurement and
the ‘usual’ BP level is more accurately esti-
mated by averaging several measurements over
1 day. In addition, the within-day variability of
the patient’s BP is able to be estimated because
multiple measurements are taken. The amount
of BP variability and the presence of BP that
does not decrease at night (non-dipping)
appear to be independent risk factors for car-
diovascular disease (CVD).2 3 If BP alone is
considered (separate to other cardiovascular
risk factors), then ambulatory BP measure-
ments are better at predicting CVD than clinic
measurements.4–9
Strengths and limitations of this study
▪ Strengths include the high event rate and good
precision for our estimates, reliable ascertainment
of outcomes with minimal losses to follow-up,
relatively untreated population rigorous statistical
analysis and clinically relevant results
▪ Limitations include an older age all male popula-
tion who were all very close in age, home advan-
tage to ambulatory systolic blood pressure (ASBP)
in the models, assumption of 20% risk reduction
with treatment. In combination these limitations
mean our estimates are ‘best case’ estimates for
this population, and the incremental value of ASBP
may be even lower in other populations.
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In parallel, clinical guidelines are increasingly recom-
mending that the decision to start therapy to lower BP be
based at least partly on the individual’s overall absolute
risk of CVD10–15 using risk prediction scores such as the
Framingham equation,16 rather than just considering the
BP level alone. Other CVD risk equations include
PROCAM,17 SCORE,18 ASSIGN19 and QRisk.20 These
risk scores incorporate information about the individual’s
gender, age, total cholesterol, high-density lipoprotein
(HDL) cholesterol, diabetes and smoking status in add-
ition to systolic BP (SBP) to arrive at their absolute risk of
a cardiovascular event within the next 5–10 years.21
Ambulatory BP measurements are only likely to be taken
after an initial BP screening in the clinic.22 Therefore, to
properly assess the value of ambulatory BP measurement,
we need to estimate the incremental value in predicting
cardiovascular disease, above and beyond risk prediction
that includes clinic BP measurement.
There is some evidence that adding ambulatory SBP
(ASBP) values to clinic SBP, but ignoring other risk
factors, signiﬁcantly improves the prediction of indivi-
duals’ cardiovascular risk.23 Other evidence suggests that
additional measurements of clinic SBP only marginally
add to a single clinic SBP measurement when this is
combined with traditional risk factors in the prediction
of an individual’s cardiovascular risk.24 The incremental
value of ASBP above and beyond risk scores based on
the Framingham equation is unknown.
We aimed to estimate the incremental value of ambu-
latory BP measurement to 10-year cardiovascular risk
scores based on the 2008 Framingham equation.16 We
tested ambulatory BP measures representing the average
and the variability of BP (see Methods section, statistical
analysis for details).
METHODS
Study design and sample
We used data from the Uppsala Longitudinal Study of
Adult Men (ULSAM). The methods for this study have
been described previously.25 Brieﬂy, ULSAM is an ongoing
longitudinal epidemiological study based on all available
men born between 1920 and 1924 in Uppsala county,
Sweden. The current paper uses baseline data from the
age 70 survey which was conducted during 1991–1995. Of
the original 1681, 1221 men in the ULSAM study who
were still alive and residing in Uppsala took part in the age
70 reinvestigations. Of these, 835 men were free of CVD at
baseline and a total of 780 men (93.4%) had valid data for
24 h ASBP and all Framingham covariates (age, total chol-
esterol, HDL cholesterol, clinic SBP, smoking status, dia-
betes status, BP-lowering treatment).
At baseline, approximately 9% and 35% were on lipid
and BP-lowering treatment, respectively.
Measurement of risk factors
Twenty-four hour ASBPs were recorded using
Accutracker 2 equipment (Suntech Medical Instruments
Inc, Morrisville, North Carolina, USA). The device was
attached to the patient’s non-dominant arm by a skilled
laboratory technician, and BP recordings were made
every 20 min for 24-h starting at 1100 h. SBP data were
edited by omitting all readings of zero and >270 and
<80 mm Hg, and all readings where the difference
between SBP and diastolic BP was less than 10 mm Hg.
Short ﬁxed clocktime intervals were used, deﬁning
daytime as 10:00 to 20:00 and night-time as midnight to
06:00 as previously suggested.26 The median number of
daytime measurements available for analysis per man
was 30 (IQR 25–33, ﬁve men had less than 14
measurements).
Clinic BP was measured in the right arm of supine
patients with a sphygmomanometer using the appropri-
ate cuff size; recordings were made to the nearest
2 mm Hg twice after 10 min rest, and the mean of the
two measurements was used for the analyses. Serum
total and HDL cholesterol levels were determined with
standardised enzymatic methods. Cigarette smoking
status was ascertained through interview reports.
Diabetes was deﬁned by applying 1985 WHO criteria to
fasting glucose and oral glucose tolerance test.
BP-lowering treatment was determined using a
questionnaire.
Follow-up and outcome events
The population was followed for up to 17.3 years since
the start of the investigation at age 70 years. The median
follow-up period was 14 years (IQR 6.6–15.5 years). End
of follow-up was at the ﬁrst of: cardiovascular event, loss
to follow-up, last follow-up visit.
Outcome variables were deﬁned using data from the
Swedish Hospital Discharge and Cause of Death
Registries. Cardiovascular morbidity was deﬁned as a
composite end point, including death or ﬁrst hospitalisa-
tion from coronary heart disease (ICD-9 codes 410–414,
or ICD-10 codes I20–I25) and stroke (ICD-9 codes 431–
436, or ICD-10 codes I61–I66). A quality control study
by the Swedish centres of the WHO MONICA study pre-
viously showed good agreement between ofﬁcial routine
mortality statistics and registration of myocardial
infarction.27
Statistical analysis
We used Cox proportional hazard models for analysis.
The proportional hazards and linearity assumptions
were tested for each covariate and found to hold.
We applied a log transformation to all ASBP variables
for consistency with the Framingham risk equation. We
included these in the models as continuous variables.
Framingham Risk Scores (FRS) were calculated using
the published equation for 10-year risk.16
Descriptive statistics were performed for traditional
risk factors and calculated FRS and unadjusted HRs esti-
mated. We built a base model for comparison which
included only FRS. We then screened a number of dif-
ferent ambulatory BP measures for incremental
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prediction by adding them one at a time to the base
model. We used likelihood ratio tests and improvements
in discrimination (c-statistic) to select ASBP measures
that were most predictive of cardiovascular risk above
and beyond FRS. Measures tested were: mean daytime,
mean night-time, minimum night-time, maximum night-
time, maximum daytime, minimum daytime, Range
daytime, coefﬁcient of variation (CV) daytime, SD night-
time, CV night-time, SD daytime, IQR daytime, IQR
night-time and the range of night-time BP. We ﬁtted
each ambulatory BP measure as one covariate (regard-
less of whether men were on BP-lowering treatment or
not). The best ‘average’ measure and the best ‘variabil-
ity’ measure for each of daytime and night-time were
then added together to the model, as well as the best
average measures for daytime and night-time together to
evaluate for further improvements. We also evaluated
equivalent diastolic BP measures in this way.
After selecting the best ASBP measures, we estimated
other metrics of incremental value compared to the
base model including HRs, measures of overall risk pre-
diction and estimated clinical effects of screening with
ambulatory BP. We estimated standardised HRs (per
SD), before and after adjustment for the FRS. We esti-
mated equivalent HRs for FRS for comparison.
The 10-year predicted risk for each man was calcu-
lated from models that included (1) FRS only and (2)
FRS and ASBP. The probability of a cardiovascular event
within 10 years was estimated by raising 10-year baseline
survival to the exponential of the sum of the linear pre-
dictors. The predicted 10-year risk from the Cox model
including FRS only tended to be higher than the actual
FRS itself. By including FRS as a covariate in the model
based on outcome data from this cohort, we were in
effect recalibrating their risk.
We assessed improvements in overall prediction by esti-
mating calibration (Groennesby-Borgan tests28) in add-
ition to the likelihood ratio tests and changes in
discrimination (c-statistic) calculated already. We also
examined reclassiﬁcation by calculating the number of
cases (CVD within 10 years) and non-cases (no CVD
within 10 years) who moved up or down across the 20%
treatment threshold) and constructed reclassiﬁcation
plots.
We estimated the difference in number of men who
would be started on treatment (or have treatment esca-
lated for those already on treatment) by comparing the
number of men above the 20% 10-year threshold when
just FRS was used in the model with the number of men
above the 20% 10-year threshold when ASBP and FRS
were used. We calculated 95% conﬁdence limits using
standard formula for paired data.29
Finally, we calculated the potential difference in the
number of cardiovascular events for every 10 000 men
screened with ASBP, using a modiﬁed version of the
method described in ref. 30 We assumed that men above
the 20% 10-year threshold would be started on treat-
ment, or have treatment escalated. We assumed that
treatment (or escalation in treatment) would have an
effect of 0.2 relative risk reduction (based on data from
ref. 31).
We ﬁrst calculated the mean of the 10-year predicted
risks for the models with the Framingham scores. We
then applied a treatment effect with a reduction in risk
of 20% to those people with estimated 10-year predicted
risks greater than 20%. Combining these treatment
reduced risks with the unchanged risks for people who
had calculated risks below the treatment threshold, we
calculated a second mean. The difference in these
means, multiplied by 10 000, provides the number of
events prevented per 10 000 screened when the risk pre-
diction models with the Framingham scores are used.
We carried out the same calculations for the models
with Framingham scores and ASBP. The number of
events prevented was compared and the difference
between Framingham only models and Framingham
and ambulatory BP calculated.
Events prevented with addition of ASBP =
(Events prevented using ASBP and clinic SBP
Events prevented using clinic SBP)
 proportion who had an event  10000
((risk2;all untreated  risk2;treatment reduced and unchanged)
 (risk1;all untreated  risk1;treatment reduced and unchanged))
 10000
We calculated 95% CIs for number of events prevented
using 2000 bootstrap samples.
SAS V.9.3 was used for all analyses.
RESULTS
We included 780 men with 412 events in our analysis
where data were available on ambulatory BP and all trad-
itional risk factors. Summary statistics are presented in
table 1. Age was not signiﬁcantly associated with CVD in
this dataset, probably because of its small variability
(most men were aged very close to 71 years). Total chol-
esterol was also not signiﬁcantly associated with CVD.
Other traditional risk factors had signiﬁcant associations
with CVD in expected directions.
Table 2 shows the improvement in CVD risk prediction
when different ASBP measures were added to a model
that included calculated FRS. The largest improvements
in overall model ﬁt and discrimination were from mean
daytime SBP. Substitution for, or addition of other, ASBP
variables did not lead to further improvements.
Evaluation of diastolic BP measures instead of SBP did
not result in further improvements.
Table 3 shows the association between FRS, mean
daytime ASBP and CVD. Before adjustment for the
other risk factor the HR was 1.43 per SD increase in FRS
and 1.31 per SD increase in ASBP. After adjustment for
the other risk factor, the HR was 1.34 per SD increase in
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FRS and 1.20 per SD increase in ASBP, demonstrating
that both were independent risk factors, but FRS was the
stronger predictor of the two.
Table 4 summarises the small improvements in overall
risk prediction for an individual when mean daytime
ASBP was added to calculated FRS in the risk model (ie,
where there is one new test that combines FRS and
ASBP). The overall calibration was better when ASBP
was added to FRS, but the actual number of events
observed vs predicted for each risk decile (used in the
Gronnesby test) appeared similar for both models (see
ﬁgure 1A, B). The very small improvements in
reclassiﬁcation are illustrated in ﬁgure 2A, B: most men
were not reclassiﬁed downwards or upwards across the
treatment threshold when ASBP was used as well as FRS.
There would have been no change in the recommenda-
tion of treatment for 98.2% (491/500) of men who did
not have an event within 10 years and 99.3% (278/280)
of men who did have an event within 10 years. These
percentages were the same when Kaplan-Meier life table
estimates were used and allowance made for censoring
(70 men without CVD died of other causes before
10 years). Figure 2A shows that of the 500 men who did
not have a cardiovascular event, 9 were correctly
Table 1 Summary data for traditional cardiovascular risk factors and ambulatory systolic BP
Characteristic
Summary
measure*
Unadjusted
HR per SD
Age (years) 71.1 (0.77) 1.04 (0.94 to 1.15)
Total cholesterol (mmol/L) 5.7 (1.3) 0.97 (0.88 to 1.07)
HDL cholesterol (mmol/L) 1.3 (0.43) 0.87 (0.79 to 0.97)
BP treatment 210/780 [26.9] 1.85 (1.51 to 2.27)
Smoking 166/780 [21.2] 1.52 (1.21 to 1.91)
Diabetes 80/780 [10.2] 1.59 (1.19 to 2.10)
Office systolic BP (mm Hg) 146 (26) 1.31 (1.19 to 1.44)
10-year FRS 0.37 (0.22) 1.46 (1.32 to 1.62)
10-year FRS>20% 733/780 [94.0] 1.75 (1.07 to 2.84)
Subsequent CVD events 412/780 [52.7]
*Values are median (IQR) or n [%].
BP, blood pressure; CVD, cardiovascular disease; FRS, Framingham Risk Score; HDL, high-density lipoprotein.
Table 2 Impact of adding ambulatory systolic BP measures to 10-year Framingham CVD risk
Ambulatory BP
measure added to
base model*
Improvement
in overall fit
(likelihood ratio
test, p value)
Improvement
in discrimination
(c-statistic)
One ABPM covariate
Mean daytime SBP 0.0006 0.011
Mean night-time SBP 0.0008 0.007
Minimum night-time SBP 0.003 0.003
Maximum night-time SBP 0.009 0.003
Maximum daytime SBP 0.04 0.003
Minimum daytime SBP 0.11 0.003
CV daytime SBP 0.39 –
SD night-time SBP 0.41 –
SD daytime SBP 0.60 –
Range daytime SBP 0.62 –
IQR daytime SBP 0.62 –
IQR night-time SBP 0.74 –
CV night-time SBP 0.74 –
Range night-time SBP 0.76 –
Two ABPM covariates
Mean daytime SBP and mean night-time SBP 0.0008 0.010
Mean night-time SBP+minimum night-time SBP 0.004 0.007
Mean daytime SBP+maximum daytime SBP 0.003 0.010
Ratio mean daytime SBP to mean night-time SBP 0.32 –
*Reference model: Framingham 10-year risk score.
ABPM, ambulatory blood pressure monitoring; BP, blood pressure; CVD cardiovascular disease; SBP, systolic blood pressure.
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reclassiﬁed downwards when ASBP was included in the
model (including one man who died at just over
8.5 years of follow-up). None were incorrectly reclassiﬁed
upwards when ASBP was included in the model.
Figure 2B shows that of the 280 men who did have a car-
diovascular event, 2 were incorrectly reclassiﬁed down-
wards and none correctly reclassiﬁed upwards when
ASBP was included in the model.
Using a risk model with just FRS, we estimated that for
every 10 000 men screened with ASBP, all 10 000 would
be treated and 723 cardiovascular events prevented
(95% CI 650 to 796 events prevented). Using a risk
model that combines FRS and ASBP, 9859 would be
treated (95% CI 9776 to 9942 treated) and 715 cardio-
vascular events prevented (95% CI 635 to 795 events
prevented). Using FRS and ASBP, 141 fewer men would
be treated (95% CI 58 to 224 less treated) and 7 fewer
events prevented (95% CI 20 fewer events prevented to
6 more events prevented).
DISCUSSION
Our analysis of data from the ULSAM found that 24-h
ABPM added little to the CVD risk prediction of the
FRS. The addition of mean daytime ASBP might lead to
fewer men started on treatment, but this may be at the
expense of fewer cardiovascular events prevented. The
estimated size of these differences is small, and the clin-
ical signiﬁcance unclear: for every 10 000 men screened
with ASBP, approximately 141 fewer men would be
started on treatment (95% CI 58 to 224 less treated) but
7 fewer cardiovascular events would be prevented (95%
CI 20 fewer events prevented to 6 more events
prevented).
Our study has several strengths. The underlying
methods used in the ULSAM study are robust. Although
this is a modestly sized study, the event rate was high and
hence our estimates had good precision. The study
population was recruited prior to widespread use of
statins and with a relatively low use of BP-lowering drugs
which means it is an appropriate population for under-
standing prognosis in an untreated population. There
were minimal exclusions due to missing data on risk
factors (less than 7% of men were missing data on
ambulatory BP or one of the FRS covariates). There was
reliable ascertainment of outcomes with minimal losses
to follow-up. We used rigorous statistical analysis using
methods that allow interpretation of the clinical signiﬁ-
cance of results.
There are also some limitations to our study. Our
study population consisted of men over the age of
65 years and most were at high risk of a cardiovascular
event. At the same time, the men in our study were all
very close in age which meant that age was not a signiﬁ-
cant predictor in this study. In populations without age
restriction, age is the most powerful predictor of cardio-
vascular risk. There is also evidence that the FRS is less
accurate for older age groups, and this may have also
caused ambulatory BP to have had more effect in our
study than in younger populations. We used the FRS as
the initial predictor for our models but this will result in
a ‘home’ advantage to ASBP (where the contribution
was decided by the data) over traditional risk factors
including clinic BP (where the contribution is ﬁxed as
decided by the Framingham Risk equation, which may
not be ideal for this data set). We assumed that treat-
ment to lower BP resulted in a 20% reduction in risk of
a cardiovascular event.31 The risk reduction may be less
for escalation of treatment (for patients who were
already on some treatment at baseline or were started
on treatment during follow-up). However, if cholesterol-
lowering effects are also considered,32 there is a
Table 3 Associations between FRS, ASBP and
cardiovascular disease
Association HR per SD (95% CI)
FRS, unadjusted 1.43 (1.30 to 1.57)
FRS, adjusted for ASBP* 1.34 (1.22 to 1.48)
ASBP, unadjusted 1.33 (1.21 to 1.46)
ASBP adjusted for FRS* 1.21 (1.10 to 1.34)
*Adjusted predictions, allowing for effects of FRS and ASBP.
BP, blood pressure; FRS, 10-year Framingham Risk Score; ASBP,
mean daytime ambulatory systolic blood pressure.
Table 4 Improvements in the overall prediction of an individual’s cardiovascular risk and effects on treatment and
cardiovascular events when mean daytime ASBP is added to FRS
Overall model
fit (LRT)
Discrimination
(change in
c-statistic)
Calibration
(p value) Reclassification* Treatment CVD events
Χ2=12.29,1df,
p=0.0006
0.011 0.27 (FRS)
vs 0.54
(FRS+ASBP)
1.8% (9/500)
non-cases correctly
classified downwards
141 less treated per
10 000 men
screened with ASBP
(95% CI 58 to 224
less treated)
7 fewer events prevented
per 10 000 men screened
with ASBP (95% CI 20
fewer events prevented to
6 more events prevented)
0.7% (2/280) cases
incorrectly classified
downwards
*Adjusting for censoring using Kaplan–Meier life table estimates did not change per cent estimates for reclassification.
ASBP, ambulatory systolic blood pressure; CVD, cardiovascular disease; FRS, Framingham Risk Score; LRT, likelihood ratio test.
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signiﬁcantly larger risk reduction with treatment, which
would more than offset this. On balance, even more
events would be prevented in the FRS alone model rela-
tive to the FRS and ASBP one. We based our estimations
of treatment effect on the assumption of one cardiovas-
cular risk assessment, but this may be repeated before
10 years, which would be likely to lead to more patients
crossing the treatment threshold with ASBP and even
smaller difference in reclassiﬁcation. Also, participants
below the absolute risk threshold who have elevated BP
may still be started on treatment, meaning less of a dif-
ference in numbers started on treatment and events pre-
vented. Finally, it is likely that not all people above the
threshold would be offered and accept treatment to
lower cardiovascular risk; again, this would lessen the dif-
ference in treatment and events prevented between the
two risk models.
In combination, these factors mean that our estimates
are ‘best-case’ estimates for this population and the
incremental value of ASBP may be even lower in other
populations, including younger populations and women.
The generalisability of these estimates is further sup-
ported by the fact that (1) Ambulatory BP did just as
badly on the performance measures that were not
looking at movement across treatment threshold, such as
change in c-statistic and likelihood ratio and (2) the risk
plots in ﬁgure 2A, B suggest that adding ambulatory BP
may still have little effect on reclassiﬁcation even if
Figure 1 (A and B) Calibration
graph showing observed and
predicted number of
cardiovascular events within
10 years, in each decile of the
risk score (A, FRS only; B, FRS
and ASBP). ASBP, ambulatory
systolic blood pressure; FRS,
Framingham Risk Score.
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thresholds were shifted so that more men were under
threshold on the basis of FRS. A recent study using simu-
lated data to evaluate the effects of changes in mean risk
on predictive and utility measures found that adding a
new predictor with HR of 1.2 per SD (similar to the HR
for ASBP in our study), resulted in little difference in
the percentage reclassiﬁed across all mean risk levels.33
We found that mean daytime ASBP had the highest
incremental value and that other ASBP measures,
including variability of BP did not add to this. Other
studies have found that visit-to-visit variation independ-
ently predicts risk of cardiovascular events3 34 and it may
be that day-to-day variation has more prognostic import-
ance than within day variation. We note that the overall
incremental value of these variability measures has not
been assessed in a similar way to the present study.
We have previously found that one additional clinic
BP (and cholesterol) measurement only minimally
improved risk prediction compared to risk factors from
the Framingham Risk equation.24 The PAMELA study
looked at improvements in the overall model ﬁt when
out of ofﬁce BP was added to clinic BP without consider-
ing other traditional risk factors.35 They found that
there was improved overall prediction, but the clinical
meaning of this is unclear. Our conclusions on the clin-
ical utility of ABPM differ from the conclusions of a cost-
effectiveness analysis undertaken in relation to the use
of ambulatory BP measurement for diagnosis of hyper-
tension.22 This modelling study assumed that patients
below the treatment threshold derived no cardiovascular
risk reduction from treatment whereas those above the
treatment threshold did. This is at odds with research
Figure 2 (A and B)
Reclassification of risk across
20% (treatment) threshold when
ambulatory systolic blood
pressure (ASBP) is included in
the prediction of 10-year risk of a
cardiovascular event (A, men
who did not develop
cardiovascular disease (CVD); B,
men who did develop CVD.
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showing a similar relative risk reduction with
BP-lowering treatment for individuals irrespective of
their pretreatment BP (down to a SBP of 110, below
which data become sparse).31
Our ﬁndings need validation in other data sets, in par-
ticular populations including women, younger people
and a wider range in age. We need to compare the
incremental value of ASBP with that of home BP meas-
urement. Future research may also assess the incremen-
tal effects of ASBP and home BP measurements on the
short term measurement variability of risk scores.
In summary, the incremental value of ASBP above FRS
appears to be at most small, at least in older men. While
selective use is reasonable, we question the recommen-
dation for universal assessment of all those being consid-
ered for use of BP-lowering therapy. FRS scores alone
are sufﬁcient to decide on the need for starting BP and
cholesterol-lowering therapy.
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